Lanari M - Search Results

1

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).

Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, Manzoni P, Boldrini A, Paolillo P, Di Fabio S, Orfeo L, Stronati M, Romagnoli C; Italian Society of Neonatology. Bollani L, et al. Among authors: lanari m. Ital J Pediatr. 2015 Dec 15;41:97. doi: 10.1186/s13052-015-0203-x. Ital J Pediatr. 2015. PMID: 26670908 Free PMC article. Review.

2

Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics.

Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, Silvestri M, Pistorio A, Chezzi C; Osservatorio RSV Study Group. Rossi GA, et al. Among authors: lanari m. Eur J Pediatr. 2007 Dec;166(12):1267-72. doi: 10.1007/s00431-007-0418-y. Epub 2007 Feb 17. Eur J Pediatr. 2007. PMID: 17308898 Free PMC article.

3

Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M. Carbonell-Estrany X, et al. Among authors: lanari m. Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):891-9. doi: 10.1007/s10096-008-0520-8. Epub 2008 Jul 16. Eur J Clin Microbiol Infect Dis. 2008. PMID: 18629558 Review.

4

Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes.

Resch B, Manzoni P, Lanari M. Resch B, et al. Among authors: lanari m. Paediatr Respir Rev. 2009 Sep;10(3):148-53. doi: 10.1016/j.prrv.2009.06.003. Epub 2009 Jul 19. Paediatr Respir Rev. 2009. PMID: 19651386 Review.

5

Respiratory syncytial virus risk factors in late preterm infants.

Lanari M, Silvestri M, Rossi GA. Lanari M, et al. J Matern Fetal Neonatal Med. 2009;22 Suppl 3:102-7. doi: 10.1080/14767050903194438. J Matern Fetal Neonatal Med. 2009. PMID: 19925369

6

Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab.

Faldella G, Alessandroni R, Aquilano G, Vandini S, Lanari M, Silvestri M, Pistorio A, Rossi GA. Faldella G, et al. Among authors: lanari m. J Chemother. 2010 Feb;22(1):30-5. doi: 10.1179/joc.2010.22.1.30. J Chemother. 2010. PMID: 20227990

7

Palivizumab prophylaxis in 'late preterm' newborns.

Lanari M, Silvestri M, Rossi GA. Lanari M, et al. J Matern Fetal Neonatal Med. 2010 Oct;23 Suppl 3:53-5. doi: 10.3109/14767058.2010.506757. J Matern Fetal Neonatal Med. 2010. PMID: 20695756 Review.

8

Clinical use of lactoferrin in preterm neonates: an update.

Manzoni P, Tarnow-Mordi W, Franco C, Gallo E, Spera AM, Rizzollo S, Decembrino L, Stronati M, Lanari M, Farina D. Manzoni P, et al. Among authors: lanari m. Minerva Pediatr. 2010 Jun;62(3 Suppl 1):101-4. Minerva Pediatr. 2010. PMID: 21089728 Review.

9

Neuroimaging in CMV congenital infected neonates: how and when.

Lanari M, Capretti MG, Lazzarotto T, Gabrielli L, Rizzollo S, Mostert M, Manzoni P. Lanari M, et al. Early Hum Dev. 2012 May;88 Suppl 2:S3-5. doi: 10.1016/S0378-3782(12)70003-8. Early Hum Dev. 2012. PMID: 22633509

10

Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants.

Lanari M, Silvestri M, Rossi GA. Lanari M, et al. Curr Drug Metab. 2013 Feb;14(2):216-25. Curr Drug Metab. 2013. PMID: 22935064 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

276 results

Search Page